What it is
AOD-9604 is a lab-made peptide copied from the tail end of human growth hormone: amino acids 177 to 191, with one extra amino acid, tyrosine, added at the front15. It was developed in Australia in the late 1990s as a possible treatment for obesity1. In obese mice and rats, it increased the breakdown of stored fat (lipolysis) and slowed weight gain47. In the mouse study, unlike whole growth hormone, it did not raise blood sugar, and in lab tests on cells it did not bind to the growth-hormone receptor4.
What makes it distinct
It was tested in people for the use it was built for, and in most of those trials it showed no benefit for weight loss over placebo1. Its developer stopped work on it for obesity in 2007, after a larger trial found no significant difference in weight loss from placebo1.
What the evidence shows
The studies in people were run by its developer, and what's available is limited to short summaries, which the FDA reviewed in 20241. In small trials, giving it by vein or by mouth to people with obesity raised a blood marker of fat breakdown but produced no significant weight loss compared with placebo1. A 12-week trial described only in a conference abstract reported more weight loss than placebo; the FDA called the differences small and of unclear meaning, and found no full publication1. A later trial, OPTIONS, enrolled 536 adults with obesity on a supervised diet and exercise program, and found no significant difference in weight loss from placebo at 12 weeks1. A safety summary of six placebo-controlled trials listed side effects such as headache, and the FDA said the reports lacked the detail needed to judge safety1. Serious events reported in one 12-week trial by mouth included several cancers; the investigators judged them unrelated, while the FDA said it had concerns about these reports and that there wasn't enough information to tell whether they were related1.
Open questions
- Injection under the skin. The FDA found no data in people for injecting it, or for applying it as a cream, only for taking it by mouth or by vein1.
- How long it lasts in the body (pharmacokinetics). The FDA found no measurements in people for any route, so no half-life in people is known1.
- Long-term safety. Obesity is a long-term condition that may need long-term treatment, and the FDA found too little information to support safety over that time1.
- Immune reactions (immunogenicity). The FDA says a peptide this size could trigger them, more so when injected under the skin, and that there's little data either way1.
- How it works. The FDA says its molecular target, and how it produces the effects seen in animals, remain unknown1.
Worth knowing
In December 2024, an FDA advisory committee voted unanimously against adding AOD-9604 to the list of ingredients that state-licensed pharmacies may use to compound drugs, after the FDA cited missing quality data, a lack of evidence that it works for obesity, and limited safety information12. The vote is advice; the FDA said it would make its final decision after considering the committee's input1. An FDA page updated in April 2026 says compounded AOD-9604 may carry a significant risk of immune reactions for some ways of taking it, and that the FDA has identified serious adverse events that may be linked to it, though it isn't clear whether AOD-9604 caused them3. In Australia, as of June 2026, it's a prescription-only medicine that is illegal to have without authority, such as a prescription6. The FDA's 2024 review also noted that it was on the World Anti-Doping Agency's list of substances banned in sport1.
Sources
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, December 4, 2024: Evaluation of AOD-9604-related bulk drug substances
- FDA Final Summary Minutes, Pharmacy Compounding Advisory Committee, December 4, 2024
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026)
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes 2001;25:1442-9 (PMID 11673763)
- Cox HD, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal 2015;7:31-8 (PMID 25208511)
- Therapeutic Goods (Poisons Standard, June 2026) Instrument 2026, commenced 1 June 2026 (Australia)
- Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000;53:274-8 (PMID 11146367)
More in Growth-hormone fragments